Prostaglandin Tri-Mix 8.33:22.5:0.833 Injection, 2 mL Vial, Anderson Compounding Pharmacy 310 Bluff City Hwy, Bristol, TN.
Anderson Compounding Pharmacy, Inc.
Lack of sterility assurance.
💊 Drugs • 11,927 recalls
Anderson Compounding Pharmacy, Inc.
Lack of sterility assurance.
Anderson Compounding Pharmacy, Inc.
Lack of sterility assurance.
Anderson Compounding Pharmacy, Inc.
Lack of sterility assurance.
Anderson Compounding Pharmacy, Inc.
Lack of sterility assurance.
Labeling: Incorrect or Missing Lot and/or Exp Date - the label contains an incorrect Exp Date.
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.
Labeling: Incorrect or Missing Lot and/or Exp Date - the label contains an incorrect Exp Date.
RemedyRepack
CGMP Deviations; Detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) - N-Methylnitrosobutyric acid (NMBA).
Labeling Not Elsewhere Classified; orange and cherry flavor packets incorrect list "natural lemon flavor" as an ingredient
Aurobindo Pharma USA
Presence of Particulate Matter: One vial was found to contain a hair.
Failed Impurities/Degradation Specifications; 18 month long term stability study.
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.
Chemical Contamination: Trace amounts of an impurity was detected in the reagent used to manufacture finished product.
Glenmark Pharmaceuticals Inc., USA
Presence Of Foreign Tablet: in a bottle of Pravastatin Sodium Tablets 20 mg.
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.
Health Solutions Pharmacy Center Inc
Lack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.
Failed Impurities/Degradation Specifications; 18 month long term stability study (manufacturer)
X-Gen Pharmaceuticals
Labeling: Label Error on Declared Strength: Side carton panel incorrectly lists the concentration as "500 mcg Clonidine Hydrochloride" rather than the correct concentration of "100 mcg Clonidine Hydrochloride" per mL.